Research map: Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring

Back to the article

Papers in this map

  1. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man · David Richard Matthews · 1985 · 31767 citations · Cited by this paper
  2. The aftermath of alcohol misuse: Linking cellular damage, suboptimal micronutrient nutrition, and organ dysfunction · 2026 · Related
  3. Role of Insulin Resistance in Human Disease · Gerald M. Reaven · 1988 · 12165 citations · Cited by this paper
  4. A dive into the untapped potential of marine compounds in counteracting neurodegeneration · 2026 · Related
  5. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease · Paul M. Ridker · 2017 · 9543 citations · Cited by this paper
  6. Mathematical modeling of T cell exhaustion in the tumor microenvironment · 2026 · Related
  7. Biochemistry and molecular cell biology of diabetic complications · Michael Brownlee · 2001 · 9147 citations · Cited by this paper
  8. C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy · 2026 · Related
  9. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  10. Circular RNA serves as an upstream regulator of the miRNA//ABCC1 axis in human cancers · 2026 · Related
  11. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework · Biomarkers Definitions Working Group · 2001 · 6761 citations · Cited by this paper
  12. Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk · 2026 · Related
  13. Markers of Inflammation and Cardiovascular Disease · Thomas A. Pearson · 2003 · 6426 citations · Cited by this paper
  14. Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders · 2026 · Related
  15. Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans · Robert V. Considine · 1996 · 6382 citations · Cited by this paper
  16. Incretin-based therapies: Effects on plasma lipids and potential mechanisms · 2026 · Related
  17. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure · Milton Packer · 2020 · 5221 citations · Cited by this paper
  18. Pharmacological activation of cGAS-STING pathway to reverse cancer drug resistance · 2026 · Related
  19. IL-6 in Inflammation, Immunity, and Disease · Toshio Tanaka · 2014 · 5139 citations · Cited by this paper
  20. RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma · 2025 · Related
  21. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD · Francesco Cosentino · 2019 · 4927 citations · Cited by this paper
  22. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis · Luca Richeldi · 2014 · 4742 citations · Cited by this paper
  23. Adipokines in inflammation and metabolic disease · Noriyuki Bob Ouchi · 2011 · 4606 citations · Cited by this paper
  24. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race · Lesley A. Inker · 2021 · 4530 citations · Cited by this paper
  25. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial · John Dormandy · 2005 · 4156 citations · Cited by this paper
  26. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis · Talmadge E. King · 2014 · 4057 citations · Cited by this paper
  27. An epigenetic biomarker of aging for lifespan and healthspan · Morgan E. Levine · 2018 · 3835 citations · Cited by this paper
  28. Inflammaging: a new immune–metabolic viewpoint for age-related diseases · Claudio Franceschi · 2018 · 3608 citations · Cited by this paper
  29. TGF-β: the master regulator of fibrosis · Xiao‐Ming Meng · 2016 · 3605 citations · Cited by this paper
  30. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia · Deepak L. Bhatt · 2018 · 3331 citations · Cited by this paper
  31. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects · Toshimasa Yamauchi · 2003 · 3198 citations · Cited by this paper
  32. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction · Jean‐Claude Tardif · 2019 · 3144 citations · Cited by this paper
  33. DNA methylation GrimAge strongly predicts lifespan and healthspan · Ake Tzu-Hui Lu · 2019 · 2779 citations · Cited by this paper
  34. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers · Michael J. Pencina · 2010 · 2489 citations · Cited by this paper
  35. Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals · Hertzel C. Gerstein · 2001 · 2475 citations · Cited by this paper
  36. Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome · Andreas Festa · 2000 · 2376 citations · Cited by this paper
  37. Colchicine in Patients with Chronic Coronary Disease · Stefan Mark Nidorf · 2020 · 2262 citations · Cited by this paper
  38. FGF-21 as a novel metabolic regulator · Alexei Kharitonenkov · 2005 · 2129 citations · Cited by this paper
  39. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association · Chiadi E. Ndumele · 2023 · 2076 citations · Cited by this paper

Source: OpenAlex (CC0)